Dermatology Times: FDA Clears Zabalafin Hydrogel’s Investigational New Drug Application for AD

Dermatology Times: FDA Clears Zabalafin Hydrogel’s Investigational New Drug Application for AD by Marie Bosslett NEWS PROVIDED BY Alphyn Biologics February 19, 2025 Alphyn Biologics announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for Zabalafin hydrogel, which is used to treat mild to moderate atopic…

Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment

Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Feb 19, 2025, 07:30 ET Zabalafin Hydrogel holds potential for first comprehensive AD treatment with safety and patient tolerability profile for long-term, worry-free, continuous use ANNAPOLIS, Md., Feb. 19, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company…

Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis

Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Dec 10, 2024, 07:30 ET Patent covers compositions and methods of use of drug formulation for Zabalafin Hydrogel ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ —  Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and…

Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology

Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology NEWS PROVIDED BY Alphyn Biologics Nov 01, 2024, 07:30 ET Paper highlights Zabalafin Hydrogel’s potential as a single topical atopic dermatitis therapy that impacts the Staphylococcus aureus component and treats all other disease symptoms across severity levels ANNAPOLIS, Md., Nov. 1, 2024 /PRNewswire/…